- Details
- Zach Klaassen interviews Jack Tay about the evolution and current practices in focal therapy for prostate cancer. Dr. Tay discusses the precision and reduced toxicity offered by focal therapy, which targets only cancerous tissues within the prostate, sparing non-cancerous areas. He highlights various treatment modalities including cryotherapy, HIFU, and newer methods like irreversible electroporat...
|
- Details
- Preston Sprenkle and Eric Kim discuss the future of prostate cancer diagnostics, emphasizing the role of genomic classifiers like PAM50 and MRI in refining patient treatment plans. Dr. Kim suggests that prostate cancer care may soon parallel advances in breast cancer, utilizing gene pathway analyses to guide treatment decisions more accurately. They explore how integrating complex biomarkers into...
|
- Details
- Preston Sprenkle discusses with Eric Kim the integration of MRI and genomic classifiers in prostate cancer management. They explore the potential of artificial intelligence (AI) to enhance diagnostic accuracy and personalization of treatment. Dr. Kim reflects on his project, which investigates correlations between MRI findings and genomic data from a large cohort, noting the challenges of consiste...
|
- Details
- Eric Kim discusses the variation in prostate cancer genomic subtypes related to MRI PI-RADS scores and racial differences. He focused on the correlations between mpMRI findings and the Decipher genomic classifier in a racially diverse cohort of men. The study revealed that MRI and Decipher scores generally correlated well, especially in non-African Americans, but this correlation was weaker among...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the 2024 updates to the NCCN Prostate Cancer Guidelines, highlighting the integration of the Decipher Genomic Classifier tests across various stages of prostate cancer management. This detailed conversation explores the progression from the 2023 guidelines, emphasizing the evolution of risk stratification tools from prognostic to the now predictive capabilit...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the publication on genomic classifier performance in intermediate-risk prostate cancer, focusing on the results of the NRG Oncology/RTOG 01-26 randomized Phase 3 trial. The study explores the use of the Decipher 22-gene genomic classifier in risk stratification, outperforming other common risk classification systems for prostatectomy and pre-treatment biopsy...
|
- Details
- Ashley Ross and Jim Hu discuss the use of genomic classifiers, specifically the Decipher Genomic Classifier, in the management of localized prostate cancer. They review its performance in larger datasets and its association with prostate cancer outcomes. The conversation also delves into the use of the Decipher Prostate Biopsy Test in men with favorable risk disease undergoing conservative managem...
|
- Details
- David Morris joins Ashley Ross in a conversation on genomics in prostate cancer specifically, in the unfavorable intermediate-risk patient. Drs Morris and Ross highlight the use of genomics in decision-making when considering what the best treatment option is for this group of individuals. They are particularly interested in determining if any of these intermediate-risk patients might actually be...
|
- Details
- Christopher Barbieri joins Matthew Cooperberg for a discussion about the molecular biology of localized prostate cancer. Dr. Barbieri explains how the underlying molecular and genomic features that separate prostate cancer subtypes can be studied using DNA sequencing and RNA sequencing. The conversation covers predictive markers including DECIPHER, PAM50, genomic mutations, and oncogenic drivers....
|
- Details
- Jason Hafron and Katie Murray join Ashley Ross in a conversation on the treatment of unfavorable intermediate-risk prostate cancer and the value of the genomic classifier useful in guiding treatment considerations. Biographies: Jason Hafron, MD, Associate Professor of Urology, The William Beaumont School of Medicine, Oakland University, Director of Robotic Surgery, Beaumont Hospital Royal Oak, Aub...
|
